glp 1 and eye issues Doctor Explains Blindness Risk (Should You Be Worried?) GLP-1 Medications and Your Vision:

Those remain separate questions, distinct from the molecular science described here.

Zero Stimulants: Provides energy and fat-burning benefits without caffeine or other stimulants

Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimers disease

Meader E, Mayer MJ, Steverding D, Carding SR, Narbad A

New England Journal of Medicine 376, 17131722

In agreement with expectations, the first outcome trial of a GLP-1RA, the ELIXA trial of the short-acting lixisenatide, an exendin-4 derivative with properties almost identical to those of exendin-4 or exenatide (stable, full agonists of the GLP-1 receptor), showed no increased cardiovascular risk in a patient group with severely increased CVD risk